Login to Your Account



Awaiting 2012 Clinical Data Readout

Merck Hands Idera Global Rights to IMO-2055 in Cancer

By Marie Powers
Staff Writer

Thursday, December 1, 2011
Merck KGaA has returned global rights to IMO-2055, a TLR9 agonist, as a cancer therapy to partner Idera Pharmaceuticals Inc. following the termination of their oncology collaboration.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription